Business Wire

NETSCOUT Combines Leading Global Threat Intelligence With Machine Learning to Protect Enterprises From Rapidly Spreading Dynamic DDoS Attacks

11.7.2023 13:05:00 EEST | Business Wire | Press release

Share

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT), a leading provider of performance management, cybersecurity, and DDoS attack protection solutions, today released its latest version of Arbor Edge Defense (AED) which includes new ML-based Adaptive DDoS Protection.

According to NETSCOUT's latest DDoS Threat Intelligence Report, there has been a significant increase in a new breed of dynamic DDoS attacks that use multiple vectors and techniques to launch botnet-based, direct-path, state exhaustion, and application-layer attacks designed to evade conventional static network and cloud-only-based DDoS defense.

Every enterprise is at grave risk today if they don’t deploy an effective DDoS solution on-premises to protect their network edge, internet-facing services, and critical stateful infrastructure such as firewalls and load balancers from these constantly evolving attacks. Attackers can send dynamic direct-path DDoS traffic at any time, and they can quickly change attack vectors during the attack making them nearly impossible to defend without the right technology. With AED’s Adaptive DDoS Protection, IT teams now have a scalable, always-on stateless packet processing solution that uses unmatched visibility into more than 50% of all internet traffic, global, real-time DDoS attack threat intelligence, decades of DDoS mitigation experience, and machine learning (ML) software intelligence to automatically detect, adapt to, and mitigate dynamic DDoS attacks.

“As cyber threats become more sophisticated and dynamic, IT teams need to out-smart bad actors with the ability to adapt and surgically block unwanted traffic at the network edge,” said Scott Iekel-Johnson, AVP, DDoS and Threat Intelligence at NETSCOUT. “With unmatched real-time visibility into global DDoS attack activity and decades of mitigation experience, no one knows more about DDoS attacks than NETSCOUT. With AED’s Adaptive DDoS Protection, enterprises can take advantage of our DDoS attack expertise and minimize unnecessary workloads that force expensive upgrades with an always-on product that can scale to protect every edge from a single pane of glass.”

Automated AED Protects Enterprises from Threats

Deployed at the Internet edge in front of any firewall, AED screens incoming and outgoing traffic using stateless packet processing, global DDoS threat intelligence, and ML to block inbound cyber threats, including DDoS attacks and other bulk malicious traffic. It protects and reduces the load on firewalls, load balancers, or VPN concentrators and stops the proliferation of malware within an organization. AED can also block outbound communications sent from compromised internal devices to sites run by bad actors to prevent data breaches and other malware activity. It contains the threat while giving the IT team time to investigate and remove it before it can cause further damage. In the event of a large volumetric DDoS attack, AED’s cloud signaling feature integrates with cloud DDoS protection providers, including NETSCOUT’s Arbor Cloud, to intelligently and automatically coordinate attack response between cloud-based volumetric protection and on-premise adaptive DDoS attack protection.

Visibility into 50% of All Internet Traffic

NETSCOUT ASERT, the company’s expert security research and DDoS attack mitigation team, works with over 500 Internet Service Providers (ISPs) to maintain a unique sensor network called ATLAS. With over 400 Tbps of international transit traffic received every second of every day from 93 countries, 600 industry verticals, and more than 31,000 autonomous systems, ATLAS provides ASERT with unmatched visibility into more than 50% of all internet traffic and real-time DDoS attack activity. ASERT analyzes the ATLAS data and distributes its findings to the Arbor Edge Defense (AED) solution via the ATLAS Intelligence Feed (AIF). AIF continually arms AED with highly curated intelligence that constantly updates the IP addresses of bots and reflectors/amplifiers actively participating in DDoS attacks around the globe. Created from real-world ASERT mitigation experience, AED’s Adaptive DDoS defense capabilities use ML-based algorithms to automatically recommend changes to attack countermeasures designed to stop dynamic DDoS attacks.

To learn more about how Adaptive DDoS Protection for AED automatically protects networks from dynamic DDoS attacks, visit our website.

About NETSCOUT

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance and availability disruptions through the company’s unique visibility platform and solutions powered by its pioneering deep packet inspection at scale technology. NETSCOUT serves the world’s largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com or follow @NETSCOUT on LinkedIn, Twitter, or Facebook.

©2023 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Visibility Without Borders, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Maribel Lopez
Manager, Marketing & Corporate Communications
+1 781 362 4330
maribel.lopez@netscout.com

Chris Shattuck
Finn Partners for NETSCOUT
+1 404 502 6755
NETSCOUT-US@FinnPartners.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye